Skip to main content

Protecting yourself from Covid-19

The recent increase in Covid-19 rates in the UK is concerning although, to some extent, an increase in rates was expected now that control measures have ended in England, with the other three UK countries also ending most control measures as well. 

We are also seeing signs of increased NHS pressures with more presentations of people with suspected or confirmed Covid-19 in primary care and hospital admissions increasing. The number of NHS staff off work due to Covid-19 is also adding to NHS pressures.

A key message for the public is that vaccination is essential. Many people have not come forwards for a booster vaccine, particularly in London and other large cities. Three doses of vaccine are essential to reduce the risks of serious illness and death from Covid-19.

A second booster programme is also now starting for the most vulnerable people in our society: people aged 75 years and over this living in care home and people who are immunocompromised. The additional booster will provide these people with greater protection from serious illness and death.

I also advise people to continue to wear a mask (preferably a FFP2 mask) when in shops and on public transport. People should also continue to self-isolate if they test positive for Covid-19 to reduce the risks of infection to others.

Given that infection rates are increasing again, people who are clinically vulnerable through age or their medical history need to be cautious about entering places where there is a high-risk of infection (i.e. crowded, indoor venues with poor ventilation).

The government should also continue with PCR testing for people with symptoms of a possible Covid-19 infection and not scale back testing as it seems to be planning from April onwards. Unfortunately, there is no easy way out of the pandemic and testing along with good infection control measures remain essential.


Comments

Popular posts from this blog

The Hidden Cost of Cheaper NHS Contracts: Losing Community Trust

NHS budgets are under considerable pressure. It is therefore unsurprising that many NHS Integrated Care Boards (ICBs) In England will aim to prioritise price in contract awards, But this approach is a significant threat to community-centred healthcare. While competitive tendering is a legally required, an excessive focus on costs in awarding NHS contracts risks overshadowing key factors such as established community trust, local expertise, and the long-term impact on continuity of care. This shift towards cheaper, often external, commercial providers threatens to cut the links between communities and their local health services. The argument that competitive tendering is solely about legal compliance, and not cost, is undermined by the very nature of such tendering, which by design encourages the lowest bid. This approach risks eroding the social fabric of local healthcare provision, where established relationships and understanding of specific community needs are essential. Establishe...

MPH Student Presentations on the NHS Care.Data Programme

As part of a session on primary care data in the Health Informatics module on the Imperial Master of Public Health Programme, I asked students to work in two groups to present arguments for and against the NHS Care.Data programme. Care.Data is an NHS programme that will extract data from the medical records held by general practitioners (GPs) in England. The Care.Data programme takes advantage of the very high level of use of electronic medical records by GPs in England. After extraction, data will be uploaded to the NHS Health and Social Care Information Centre (HSCIC). The data will then be used for functions such as health care planning, monitoring disease patterns and research. The programme has been controversial with proponents arguing that the programme will bring many benefits for the NHS and the population of England; and opponents arguing it is a major breach of privacy. You can view the two presentations to help inform you further about these arguments: Arguments fo...

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...